{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:41:07Z","timestamp":1791283267196,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","award":["175:1298-304"],"award-info":[{"award-number":["175:1298-304"]}],"id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Millennium Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:34:17Z","timestamp":1670358857000},"page":"e171-e181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-4610","authenticated-orcid":false,"given":"Michael A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-5937","authenticated-orcid":false,"given":"Caitlin L.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Omel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania T.M.","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renda H.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn Marie","family":"Stull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.003_bib0001","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.12.003_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ejh.12813","article-title":"Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy","volume":"98","author":"Teh","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.12.003_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.12.003_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2022.12.003_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2022.12.003_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and temporal changes in risk of invasive pneumococcal disease in adults with Hematological Malignancies: results from a Nationwide 16-Year cohort study","volume":"72","author":"Andersen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.12.003_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.htct.2019.02.005","article-title":"Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan","volume":"41","author":"Zahid","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.clml.2022.12.003_bib0009","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.003_bib0011","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0013","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed Multiple Myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0014","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-134923","article-title":"Predictive markers of high-grade or serious treatment-emergent infections with Daratumumab-based regimens in Newly Diagnosed Multiple Myeloma (NDMM)","volume":"136","author":"van de Donk","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.003_bib0016","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.12.003_bib0017","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/21645515.2018.1534516","article-title":"Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls","volume":"15","author":"Mustafa","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clml.2022.12.003_bib0018","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.003_bib0019","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.003_bib0020","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2020.05.024","article-title":"Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: results of a prospective clinical study","volume":"38","author":"Stoma","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.clml.2022.12.003_bib0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.17294\/2330-0698.1453","article-title":"Multiple Myeloma baseline immunoglobulin G level and pneumococcal vaccination antibody response","volume":"4","author":"Thompson","year":"2017","journal-title":"J Patient Cent Res Rev"},{"key":"10.1016\/j.clml.2022.12.003_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.003_bib0023","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.003_bib0024","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clml.2016.06.006","article-title":"Vaccination in Multiple Myeloma: review of current literature","volume":"16","author":"Alemu","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.003_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.17294\/2330-0698.1415","article-title":"Multiple Myeloma vaccination patterns in a large health system: a pilot study","volume":"4","author":"Alemu","year":"2017","journal-title":"J Patient Cent Res Rev"},{"key":"10.1016\/j.clml.2022.12.003_bib0026","doi-asserted-by":"crossref","first-page":"e20567","DOI":"10.1200\/JCO.2020.38.15_suppl.e20567","article-title":"Healthtree patient portal mediated myeloma patient-reported vaccination and antibiotic use","volume":"38","author":"Thompson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0027","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/vaccines8040722","article-title":"Vaccination during the First Diagnosis of Multiple Myeloma: a cohort study of the French National Health Insurance Database","volume":"8","author":"Tournaire","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clml.2022.12.003_bib0028","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2217\/fon-2019-0013","article-title":"INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma","volume":"15","author":"Costello","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0029","unstructured":"Puig N, Abonour R, Davies FE, et al. Real-world duration of treatment (DOT) with lenalidomide-dexamethasone (Rd)-based regimens in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): outcomes from the global INSIGHT MM study. 2021 EHA2021:Abstract EP985."},{"key":"10.1016\/j.clml.2022.12.003_bib0030","unstructured":"Organisation for Economic Co-operation and Development. Influenza vaccination rates. https:\/\/data.oecd.org\/healthcare\/influenza-vaccination-rates.htm. Accessed 15 July 2021."},{"key":"10.1016\/j.clml.2022.12.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/2150132720962870","article-title":"Annual wellness visits and influenza vaccinations among older adults in the US","volume":"11","author":"J\u00f8rgensen","year":"2020","journal-title":"J Prim Care Community Health"},{"key":"10.1016\/j.clml.2022.12.003_bib0032","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0033","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.12.003_bib0034","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.575168","article-title":"Real world experience of Daratumumab: evaluating Lymphopenia and adverse events in Multiple Myeloma patients","volume":"10","author":"Cottini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.12.003_bib0036","unstructured":"Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden. 2021. https:\/\/www.cdc.gov\/flu\/about\/burden\/past-seasons.html. Accessed 1 June 2021."},{"key":"10.1016\/j.clml.2022.12.003_bib0037","unstructured":"Centers for Disease Control and Prevention. Pneumococcal Disease - Surveillance and Reporting. https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html. Accessed 1 June 2021."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:20Z","timestamp":1761871280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017487"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}